FORD KATHLEEN 4

What Happened Kathleen Ford, Chief Operating Officer of Kura Oncology (KURA), sold 2,257 shares in an open-market transaction on May 19, 2026. The weighted-average sale price was $9.08 per share, for total proceeds of approximately $20,483. This was a sale (routine disposition) rather than a purchase.

Key Details

• Transaction date: May 19, 2026 (reported on Form 4 filed May 20, 2026).
• Price: Weighted average $9.08; executed in multiple trades at prices ranging from $8.97 to $9.17 (filing includes undertaking to provide exact breakdown on request).
• Shares sold: 2,257; proceeds ≈ $20,483.
• Shares acquired: Those 2,257 shares were acquired on May 17, 2026 under Kura’s Employee Stock Purchase Plan (per filing footnote).
• Plan: Sale was made pursuant to a Rule 10b5-1 trading plan adopted by Ms. Ford on August 29, 2025 (footnote).
• Ownership after transaction: Not specified in the provided filing.
• Timeliness: Form 4 was filed the day after the transaction (timely under Form 4 rules).

Context This filing reports a sale executed under a pre-established 10b5-1 plan, which is commonly used by insiders to schedule trades in advance and is generally considered routine. The filing notes the shares sold were recently acquired via the company ESPP, which can explain a quick subsequent disposition; do not read this single sale as an indicator of company performance on its own.